Mylan and Biocon gain approval for Herceptin biosimilar in India while Roche and ImmunoGen gain approval for Herceptin-DM1 combination Kadcyla in Europe.
Teva Pharmaceutical, Eli Lilly, Novartis, and AstraZeneca will lose patent exclusivity for five blockbuster drugs in 2014. Let’s take a closer look at what the future holds for these four companies.
The S&P 500 succumbs to investors' fears and dips for a third straight session. Find out why OncoMed Pharmaceuticals, Unilife, and Tesla all motored higher by double-digits and bucked the negativity.
Let’s see why these two stocks -- Sanofi and Unilife -- could make health-care headlines today.
Teva (TEVA) is losing patent protection for its multi-billion dollar blockbuster Copaxone next year, opening the door for Mylan (MYL) to win market share with its generic version.
Thinking about investing in Pfizer? Then you need to know these 3 things that could put the company on a collision course with Regeneron, Sanofi, Amgen, and Novartis before 2014.
Cooper Companies reported earnings and revenues for the fiscal third quarter ended Jul 31, 2013, both of which surpassed the Zacks Consensus Estimate
We are presenting three mutual funds, each of which invests globally and have high returns, as well as the best possible Zacks Rank.
The company announced revenue growth in its earnings call, but that doesn’t necessarily mean investors should rest easily
Will new breast-cancer treatments from Pfizer, Novartis, and Eli Lilly usher in a new age of targeted drugs, fragmenting a market that is currently dominated by Roche?
Novartis (NVS) outlined a few strategic plans at its analyst day held recently, to position it more strongly in the pharmaceutical business and increase return for shareholders.
The NAS designation provides Tecfidera with 10 years of regulatory exclusivity in the EU.
Novartis (NVS) shares received a shot in the arm after management detailed a $5 billion share repurchase program.